<DOC>
	<DOCNO>NCT01777750</DOCNO>
	<brief_summary>The primary goal treatment acute myocardial infarction reperfuse ischemic myocardium reduce infarct size . Animal data human data suggest whole-body cooling temperatures 35°C revascularisation additionally reduce infarct size therefore improve outcome patient . The purpose study determine combine cool strategy start out-of-hospital arena able reduce infarct size acute myocardial infarction .</brief_summary>
	<brief_title>Cooling Myocardial Infarction</brief_title>
	<detailed_description>Background : Contemporary therapy patient on-going ST-elevation myocardial infarction ( STEMI ) reperfuse ischemic myocardium soon possible reduce infarct size associate complication . A recent pilot-study show significant reduction infarct size induction pre-reperfusion hypothermia . Objectives : To demonstrate reduction infarct size/myocardium risk ( measure magnet resonance image ) patient ST-Elevation myocardial infarction strategic temperature management use external cooling pad out-of-hospital set continuation cold saline central venous catheter cool hospital . In parallel translational study , molecular effect rapid early cooling inflammatory process culprit lesion site define . Methodology : Randomized , prospective , controlled trial Number subject : 120 patient ( 60 per group ) Investigational medical device : EMCOOLS flex pad external cooling pad , consist multiple cool cell fill patented cooling gel . EMCOOLS flex pad use out-of-hospital set initiate cooling . The Philips RTx Endovascular System™ endovascular thermal control system circulate cooled saline indwell central venous catheter closed-loop manner . It use combination 1-2 litres intravenous cold saline induce hypothermia 35 degree Celsius . Duration : One hour successful revascularization cool procedure stop , subject cover blanket allow passively re-warm . Clinical follow-up 180 day . Primary endpoint : Myocardial infarct size ( percentage myocardium risk ) assess cardiac MRI 4±2 day . Influence target temperature management coronary macrophage monocyte well impact plasma level immune cell chemotaxis activation .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Age 18 75 year Immediate transfer cathlab possible Anterior inferior STsegment myocardial infarction STSegment elevation &gt; 0.2mV 2 anatomically contiguous lead Duration symptom &lt; 6 hour Participation another study Patients present cardiac arrest/cardiogenic shock Tympanic temperature &lt; 35.0°C prior enrolment Thrombolytic therapy Previous MI Previous PCI coronary artery bypass graft Severe heart failure presentation ( defined New York Heart Association ( NYHA ) functional class III IV ) , Killip class II IV Clinical sign active infection Endstage kidney disease hepatic failure Recent stroke ( within past six month ) Conditions may exacerbate hypothermia , haematological dyscrasia , oral anticoagulant treatment international normalized ratio &gt; 1.5 , severe pulmonary disease Pregnancy Women childbearing potential Allergy meperidine , buspirone , magnesium , polyvinyl chloride Use monoamine oxidase inhibitor selegiline previous 14 day absolute contraindication MRI ( PM , ICD , ferromagnetic implant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial Reperfusion Injury</keyword>
	<keyword>Reperfusion Injury</keyword>
	<keyword>Anterior Wall Myocardial Infarction</keyword>
	<keyword>Inferior Wall Myocardial Infarction</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Myocardial Ischemia</keyword>
</DOC>